Eli Lilly 利益（をあげる） （警官の）巡回区域，受持ち区域 helps 緩和する 投資家 関心s over growth
By Saumya Joseph and マナs Mishra
Jan 30 (Reuters) - Eli Lilly and Co 地位，任命するd a higher-than-推定する／予想するd fourth-４半期/4分の1 利益（をあげる） on Thursday on strong 需要・要求する for 糖尿病 麻薬 Trulicity and psoriasis 治療 Taltz, helping 緩和する 投資家 関心s over the 衝撃 of 猛烈な／残忍な 競争 for its growth 製品s.
Sales of Trulicity 殺到するd nearly 31% to $1.21 billion in the ４半期/4分の1, accounting for about a fifth of total sales and より勝るing 期待s of $1.15 billion, によれば Refinitiv data. Taltz sales rose about 37% to $420 million, also （警官の）巡回区域，受持ち区域ing 見積（る）s of $395.7 million.
The results 緩和する 投資家s' "誇張するd 関心s" over the 開始する，打ち上げる of Novo Nordisk's once-daily oral 糖尿病 pill, Rybelsus, Citi 分析家 Andrew Baum said.
Rybelsus, 認可するd late last year, is 推定する／予想するd to be embraced by 患者s with an aversion to needles used to 配達する 治療s such as Trulicity.
"The injectable GLP-1 class continues to 追加する new 患者s にもかかわらず the 入ること／参加（者） of a new oral therapy," 長，指導者 財政上の Officer Joshua Smiley said on a 会議／協議会 call with 分析家s.
The Indianapolis drugmaker has been leaning on newer 薬／医学s to 刺激（する） growth while going on a 取引，協定-making spree to build its 治療 大臣の地位, as older 薬／医学s such as erectile dysfunction 治療 Cialis lose market 株 to generic 競争.
"With Trulicity and Taltz looking very strong 親族 to 期待s and growth not 存在 鈍らせるd by any 競争 or pricing, that's more the 焦点（を合わせる） for 投資家s," UBS 分析家 Navin Jacob told Reuters.
Lilly 株 最初 fell about 1% after it 発表するd it was not planning その上の 裁判，公判s of the 実験の 肺 癌 麻薬 pegilodecakin it acquired with its $1.6 billion 購入（する） of Armo Biosciences 予定 to disappointing 裁判，公判 results.
株 later 逆転するd course and were up 1.5%.
Although the company will continue to 追求する "higher-危険, high reward" 麻薬 候補者s such as pegilodec akin, these will be a smaller part of the 大臣の地位 in the 未来, said 長，指導者 科学の Officer Daniel Skovronsky.
Earlier this month, Lilly said it was 的ing 概略で one $1 billion to $5 billion 取引，協定 every ４半期/4分の1 in 2020.
大統領 David Ricks told Reuters the company 目的（とする）s to build on last year's 取得／買収 of Loxo Oncology and 焦点（を合わせる） on 的d 癌 麻薬s going 今後. "We see a lot of 滑走路 there."
Its 最近の $1.1 billion 取得／買収 of 肌 病気 specialist Dermira Inc helped it わずかに raise its 2020 歳入 予測（する） to between $23.7 billion and $24.2 billion from $23.6 billion and $24.1 billion
除外するing items, the company earned $1.73 per 株, （警官の）巡回区域，受持ち区域ing 分析家s' 普通の／平均（する） 見積（る） by 21 cents.
歳入 rose 8.5% to $6.11 billion, above 期待s of $5.91 billion. (報告（する）／憶測ing by マナs Mishra and Saumya Sibi Joseph in Bengaluru and Carl O'Donnell in New York; Editing by Arun Koyyur and 法案 Berkrot)
